Transcranial Photobiomodulation for ADHD
This study is looking at how transcranial photobiomodulation (tPBM) might help adults with Attention Deficit Hyperactivity Disorder (ADHD). tPBM uses a special light (1064-nm light) directed at the forehead to improve brain function. Researchers want to see if this treatment can improve thinking skills and brain oxygenation in people with ADHD. You might be able to join if you are an adult between 18 and 44 years old, have a medical history of ADHD, and speak English. The study will be considered successful if participants receiving the active tPBM show better attention, impulse control, and working memory, along with improved brain oxygenation. The current status of this study is unclear.
- Study design
- This is a double-blind, sham-controlled study, meaning neither you nor the researchers will know if you are receiving the active treatment or a placebo (sham device). It plans to enroll 140 participants.
- What's involved
- You would attend three in-person sessions where you receive weekly tPBM treatments. You will also complete cognitive tests and a questionnaire at the beginning, after the treatments, and one online follow-up visit four weeks later.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will have one online follow-up visit four weeks after your last treatment session to assess ADHD symptoms.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Effects of Transcranial Photobiomodulation in ADHD
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Performance on the Continuous Performance Task1. Pre-Treatment: Baseline (Visit 1). 2. Post-treatment: Two weeks later (Visit 3).
The Continuous Performance Task is a widely-used cognitive measure to evaluate sustained attention, vigilance, and response control. Participants respond to letters presented on a computer screen and inhibit their responses to the letter X. There is no score on a scale. An increase in Correct Rejections on CPT = better inhibition = better outcome of treatment.
- Prefrontal oxygenation (functional near-infrared spectroscopy)1. Pre-Treatment: Baseline (Visit 1). 2. Post-treatment: Two weeks later (Visit 3).
Participants will wear a head-mounted functional near-infrared spectroscopy device that records changes in the concentrations of oxygenated hemoglobin potentially resulting from the treatment.
- Scores on the Adult ADHD Self-Report Scale (ASRS) questionnaire1. Pre-Treatment: Baseline (Visit 1). 2. Post-treatment: Two weeks later (Visit 3). 3. Follow-up: Four weeks later (Online).
The ASRS is an 18-question self-assessment tool created by the World Health Organization (WHO) which evaluates symptom severity of ADHD. Minimum score=18; maximum score=90; high score = more ADHD symptoms; lower score after treatment = better outcome.